Abstract
Small interfering RNA (siRNA) has been demonstrated to be a powerful tool for silencing post-transcriptional gene expression, and thus exhibits great potential in cancer gene therapy. However, siRNA technology has not become an established strategy for cancer treatment, as it is a considerable challenge to deliver siRNA to the targeting sites. In this review, barricades in the systemic delivery of siRNA were systematically introduced, from pharmacokinetics, biodistribution and intracellular behavior. Meanwhile, current and potential strategies for overcoming the barricades were elucidated, including chemical modification of siRNA, nanomaterial-based delivery systems, and targeting and stimuli-responsive smart carriers. In conclusion, the siRNA-based gene silencing drug will gain an important position for treating human diseases if we can solve the gap between ideal and reality.
Keywords: siRNA, gene silencing, barricade, delivery system, smart carrier.
Current Pharmaceutical Biotechnology
Title:Ideal and Reality: Barricade in the Delivery of Small Interfering RNA for Cancer Therapy
Volume: 17 Issue: 3
Author(s): Di Wu, Haobo Han, Zhen Xing, Jianxu Zhang, Li Li, Wei Shi and Quanshun Li
Affiliation:
Keywords: siRNA, gene silencing, barricade, delivery system, smart carrier.
Abstract: Small interfering RNA (siRNA) has been demonstrated to be a powerful tool for silencing post-transcriptional gene expression, and thus exhibits great potential in cancer gene therapy. However, siRNA technology has not become an established strategy for cancer treatment, as it is a considerable challenge to deliver siRNA to the targeting sites. In this review, barricades in the systemic delivery of siRNA were systematically introduced, from pharmacokinetics, biodistribution and intracellular behavior. Meanwhile, current and potential strategies for overcoming the barricades were elucidated, including chemical modification of siRNA, nanomaterial-based delivery systems, and targeting and stimuli-responsive smart carriers. In conclusion, the siRNA-based gene silencing drug will gain an important position for treating human diseases if we can solve the gap between ideal and reality.
Export Options
About this article
Cite this article as:
Wu Di, Han Haobo, Xing Zhen, Zhang Jianxu, Li Li, Shi Wei and Li Quanshun, Ideal and Reality: Barricade in the Delivery of Small Interfering RNA for Cancer Therapy, Current Pharmaceutical Biotechnology 2016; 17 (3) . https://dx.doi.org/10.2174/1389201017666151029110710
DOI https://dx.doi.org/10.2174/1389201017666151029110710 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Dual Roles of Sulforaphane in Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Estrogen-Related Receptors as Emerging Targets in Cancer and Metabolic Disorders
Current Topics in Medicinal Chemistry Brain Tumor Causes, Symptoms, Diagnosis and Radiotherapy Treatment
Current Medical Imaging New Approaches to Target Cancer Stem Cells: Current Scenario
Mini-Reviews in Medicinal Chemistry Predicting LncRNA-Disease Association Based on Generative Adversarial Network
Current Gene Therapy Characterization of Solid Lipid Nanoparticles Containing Caffeic Acid and Determination of its Effects on MCF-7 Cells
Recent Patents on Anti-Cancer Drug Discovery Neuro-Transmitters in the Central Nervous System & their Implication in Learning and Memory Processes
Current Medicinal Chemistry SAR, QSAR and Docking of Anticancer Flavonoids and Variants: A Review
Current Topics in Medicinal Chemistry Genetic and Epigenetic Studies for Determining Molecular Targets of Natural Product Anticancer Agents
Current Cancer Drug Targets Control of Neuropathic Pain by Immune Cells and Opioids
CNS & Neurological Disorders - Drug Targets Acridone-based Antitumor Agents: A Mini-review
Anti-Cancer Agents in Medicinal Chemistry uPAR as Anti-Cancer Target: Evaluation of Biomarker Potential, Histological Localization, and Antibody-Based Therapy
Current Drug Targets Design of Combretastatin A-4 Analogs as Tubulin Targeted Vascular Disrupting Agent with Special Emphasis on Their Cis-Restricted Isomers
Current Pharmaceutical Design Oncologic Imaging End-Points for the Assessment of Therapy Response
Recent Patents on Anti-Cancer Drug Discovery Improving Cancer Chemotherapy with Modulators of ABC Drug Transporters
Current Drug Targets Enediyne Anticancer Antibiotic Lidamycin: Chemistry, Biology and Pharmacology
Anti-Cancer Agents in Medicinal Chemistry Nanomaterials for Photohyperthermia: A Review
Current Pharmaceutical Design Matrix Metalloproteinase Inhibitors: New Challenges in the Era of Post Broad-Spectrum Inhibitors
Current Pharmaceutical Design Therapeutic Potential of Essential Oil-based Microemulsions: Reviewing State-of-the-art
Current Drug Delivery Recent Patents of Gene Sequences Relative to the Phosphatidylinositol 3-kinase / Akt Pathway and their Relevance to Drug Discovery
Recent Patents on DNA & Gene Sequences